Opthea Secures Up To US$170 Mln In Financing For OPT-302 In Wet AMD

Opthea Limited (OPT, OPT.AX) said that it has secured up to US$170 million in non-dilutive financing to advance the ongoing phase 3 clinical trials and pre-commercialization activities of OPT-302 for wet age-related macular degeneration. The financing consists of a US$120 million commitment and has an option to increase funding by a further US$50 million.

If OPT-302 is approved in a major market, Carlyle and Abingworth will be eligible to receive fixed success payments and variable success payments of 7% on annual net sales, which terminate after reaching four times the funded amount.

Opthea retains full worldwide commercial rights for OPT-302 and has the option to prepay its obligations in full at any time.

OPT-302 is a first-in-class intravitreally administered biologic "trap" inhibitor of vascular endothelial growth factors C (VEGF-C) and D (VEGF-D) currently being investigated in two concurrent Phase 3 pivotal registrational trials that will each enroll ~990 treatment naïve patients, in combination with two approved anti-VEGF-A treatments, ranibizumab (ShORe trial) and aflibercept (COAST trial). OPT-302 has the potential to be positioned as complementary and agnostic with any combined anti-VEGF-A therapy for the treatment of wet AMD.

In addition, Opthea has received commitments for US$90 million through a private institutional equity placement for new shares and launched an A$5 million Share Purchase Plan.

Opthea is expected to be fully funded through pivotal Phase 3 topline data and pre-commercial activities and retains full worldwide commercial rights to OPT-302.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration said it now intends to review only a small subset of new emergency use authorization or EUA requests for diagnostic tests. As per an updated COVID-19 test policy with a view to ensure continued access to tests, the regulator further urged developers of all test types seeking marketing authorization to pursue traditional premarket review for most test types. Netflix, Inc. said it is adding a new feature to offer a more personalized mobile games experience on the platform. In a statement, Sophia Yang, Product Manager, Mobile Games, said the company is rolling out the ability to create game handles, with which members will be able to create a unique public username. This can be used across all Netflix games. General Motors Co. has delayed its plan to require employees to return to office many days a week until next year, reports said citing an internal memo signed by CEO Mary Barra. Last week, the company had announced that corporate workers would be required to return to respective offices at least three days a week, beginning later this year, as the COVID-19 pandemic eases.
Follow RTT